The Canadian government has sanctioned a startup to export substances derived from psychedelics to Australia for therapeutic use. Optimi Health Corp. has been assigned to transport pills laced with psilocybin, an extract from magic mushrooms, and MDMA, as approved by the health department.
The growing demand reaches beyond the local magic mushrooms Ontario. Other countries are following in Canada’s footsteps, beginning to investigate and authorize the medicinal use of serotogenic compounds.
You can confidently buy psychedelics online in Canada, and unlock your inherent potential through trusted sources.
[toc]Main Takeaways:
- Vancouver-based startup Optimi Health has been given a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms as a treatment for chronic depression.
- The treatment includes three sessions over a period of five to eight weeks, with each session lasting about eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based small firm, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain a first-mover advantage.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical trial use. A spokesperson for Canada’s health department could not confirm if these exports were for regular patient use and chose not to reveal the companies due to security issues.
This accomplishment places Optimi among a handful of international suppliers, with the current market favoring clinical over recreational uses.
What’s in the Pill?
Although the company has not revealed the species of mushroom used in the pill, they are known to work with various strains like Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, home to roughly 3,000 individuals, is situated three hours to the east of Vancouver.
Australia’s Connection with Psychedelic Mushrooms
Statistics suggest that 1 in every 5 Australians aged 16 to 85 might encounter a mental health issue. PTSD (post-traumatic stress disorder) is anticipated to impact 11% of Australians at some point, with anxiety disorders affecting 17% of the populace.
A broad spectrum of treatment methods exists for mental health issues, but not all are efficacious for every person. Patients who do not respond to certain therapies may find it difficult to locate an effective method, heightening their susceptibility.
Unraveling the Procedure
Australia is at the forefront in utilizing psilocybin, permitting licensed psychiatrists to employ this regulated substance in treating PTSD and treatment-resistant depression.
In a notable decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic applications. The TGA affirmed that these substances are safe when used under medical supervision for patients struggling with severe mental ailments.
This advancement has been a game-changer for numerous mental health professionals and investigators. The usage of these substances will be strictly overseen; it’s not as simple as taking a pill and departing.
The treatment protocol typically includes three sessions over a span of five to eight weeks. Each session endures about eight hours, with the therapist accompanying the patient all through.
Canada’s Role in Psilocybin Research
Canada has surfaced as a key player in psilocybin research, considerably broadening our understanding of this substance. Health Canada, in collaboration with various institutions, is leading the quest for psilocybin’s therapeutic potential in treating diverse mental health conditions.
Research institutions are no longer required to classify these substances as illegal or rely on unregulated dispensaries or mushroom shops. The government currently permits certain institutions to grow shrooms for research objectives.
The increased accessibility to substances previously labelled as harmful enables researchers to deepen their grasp of their prospective advantages to numerous individuals.
A Cyclical Surge
The potential of this field was first acknowledged in the 1950s as a solution for mental health problems and substance misuse, particularly alcoholism. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneering figures in this early research carried out at the Weyburn The Saskatchewan Mental Hospital. This institution saw noteworthy progress under the leadership of then-Premier Tommy Douglas, who granted the medical community considerable freedom to test their medical hypotheses.
Dr. Osmond and Dr. Hoffer undertook studies with LSD, mescaline, and peyote as potential alternatives to the harsh procedures of electroshock and lobotomy. Their research took unexpected paths, leading to them advocating for doctors, nurses, and support staff to experiment with these substances.
Canadian Institutes of Health Research
Through its Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to investigate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in advanced-stage cancer patients at end-of-life | University of Toronto | Sarah Hales | $928,643 |
| Understanding the mechanisms of psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This financial support for research will enable a deeper understanding of the benefits of controlled substances. The Canadian Drugs and Substances Strategy (CDSS), launched by the Government of Canada, has made this funding possible.
Further Psychedelic Research
Psychiatrists in Vancouver have begun a phase III clinical trial of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The therapy includes three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. This trial is considered a historical milestone as it’s the first clinical evaluation of an illegal
It’s been over four decades since a psychedelic substance was last studied.
Deconstructing Psilocybin
Psilocybin is a psychedelic compound that naturally occurs in certain species of mushrooms. Upon consumption, it is metabolized into psilocin, which stimulates the serotonin 5-HT2a receptors found on the cortical pyramidal cells located in the brain, acting as the key processing centers.
Local authorities are investigating this substance for its potential ability to aid in treating depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual enlightenment.
Why is it Potentially Effective in Treating Depression, PTSD, and Others?
The substance’s active component interacts with various brain regions, making it potentially beneficial for numerous mental conditions. This therapy has already been used to treat numerous patients in Canada and Australia, showing promising results with minimal side effects such as temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound acts as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, which plays a key role in mood regulation and emotional processing.
- Regulation of Default Mode Network (DMN): The substance decreases DMN activity, promoting introspection, enhancing emotional flexibility, and mitigating rigid thought patterns.
- Stimulation of Prefrontal and Limbic Regions: The compound’s antidepressant effects stem from its influence on the prefrontal and limbic brain regions, including the amygdala. In depressed individuals, the responsiveness to emotional stimuli is often lowered. The compound increases the reaction to positive emotional stimuli in the right amygdala and normalizes or reduces the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: The substance fosters feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience could allow individuals to safely face and process deep-seated emotions, traumatic memories, or existential concerns within a supportive context.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that it can result in enduring positive changes, such as improved wellness, heightened life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Retailers?
Are you interested in how this substance might affect your mental health? Explore magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, promotes creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts overall wellness and improves life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes clarity, creativity, and concentration. Contains a strong mix of clinical-strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
International Recognition of Psilocybin
Canada isn’t the only nation advocating for magic mushrooms to address mental health concerns. Countries like Australia are also embracing the use of these hallucinogens to treat conditions such as depression and PTSD. They procure premium psychedelic capsules from trustworthy sources. Under the right supervision, patients can significantly improve their life quality. Magic Mushies Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA have therapeutic potential to enhance mental well-being. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA cultivates empathy and is beneficial in PTSD therapy. It exhibits potential in improving emotional processing and
Despite being labeled as a controlled substance, it has demonstrated beneficial therapeutic results.
Is this treatment accessible to all Australians?
No. In Australia, prospective users must undergo an evaluation to assess their eligibility for this substance. This assessment takes into account factors such as pre-existing heart conditions, previous instances of psychosis, and others. Only patients who have not found relief from conventional treatments for conditions such as depression, anxiety, or PTSD can avail of this treatment.
What are the implications of Canada’s mushroom exports?
Canada is strategically positioning itself to lead the psychedelics market, akin to its approach with cannabis. This could encourage more companies to produce high-quality products. As a result, Canada might become a leading player in the hallucinogen market, strengthen its economy, and provide easier access to treatments for other countries. It would also prevent these countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles That Might Pique Your Interest:
